Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Fennec Pharmaceuticals (FENC) over the last 14 years, with Q3 2025 value amounting to $1.7 million.

  • Fennec Pharmaceuticals' Cash from Financing Activities rose 43125.0% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.4 million, marking a year-over-year decrease of 34007.4%. This contributed to the annual value of -$13.6 million for FY2024, which is 30510.7% down from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Cash from Financing Activities is $1.7 million, which was up 43125.0% from -$284000.0 recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Cash from Financing Activities ranged from a high of $19.8 million in Q3 2022 and a low of -$12.2 million during Q4 2024
  • In the last 4 years, Fennec Pharmaceuticals' Cash from Financing Activities had a median value of $201000.0 in 2023 and averaged $1.0 million.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Cash from Financing Activities soared by 118666.67% in 2023, and later crashed by 68652.85% in 2024.
  • Over the past 4 years, Fennec Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $824000.0 in 2022, then surged by 595.39% to $5.7 million in 2023, then plummeted by 313.12% to -$12.2 million in 2024, then soared by 114.32% to $1.7 million in 2025.
  • Its Cash from Financing Activities was $1.7 million in Q3 2025, compared to -$284000.0 in Q2 2025 and $359000.0 in Q1 2025.